Drug Patents owned by Genentech Inc

1. List of Cotellic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7803839 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Nov, 2029

(6 years from now)

US10478400 GENENTECH INC Immediate-release tablets containing combimetinib and methods of making and using the same
Jun, 2036

(13 years from now)

US10590102 GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Jun, 2036

(13 years from now)

US11254649 GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
Jun, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8362002 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Oct, 2026

(3 years from now)

US8362002

(Pediatric)

GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Apr, 2027

(4 years from now)

US7803839

(Pediatric)

GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
May, 2030

(7 years from now)

US11087354 GENENTECH INC Combination therapies
Jun, 2034

(11 years from now)

US11087354

(Pediatric)

GENENTECH INC Combination therapies
Dec, 2034

(11 years from now)

US10478400

(Pediatric)

GENENTECH INC Immediate-release tablets containing combimetinib and methods of making and using the same
Dec, 2036

(13 years from now)

US10590102

(Pediatric)

GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Dec, 2036

(13 years from now)

US11254649

(Pediatric)

GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
Dec, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 10, 2022
New Indication (I) Oct 28, 2025
M Jul 28, 2025
Pediatric Exclusivity (PED) Jan 28, 2026

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Market Authorisation Date: 10 November, 2015

Treatment: Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

More Information on Dosage

2. List of Esbriet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9561217 GENENTECH INC Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
Jan, 2022

(1 year, 8 days ago)

US7767225 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Sep, 2026

(3 years from now)

US7988994 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Sep, 2026

(3 years from now)

US8753679 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Sep, 2026

(3 years from now)

US7767700 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(4 years from now)

US8420674 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(4 years from now)

US7696236 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(4 years from now)

US8383150 GENENTECH INC Granulate formulation of pirfenidone and pharmaceutically acceptable excipients
May, 2028

(5 years from now)

US7566729 GENENTECH INC Modifying pirfenidone treatment for patients with atypical liver function
Apr, 2029

(6 years from now)

US7635707 GENENTECH INC Pirfenidone treatment for patients with atypical liver function
Apr, 2029

(6 years from now)

US8609701 GENENTECH INC Pirfenidone treatment for patients with atypical liver function
Apr, 2029

(6 years from now)

US8592462 GENENTECH INC Pirfenidone treatment for patients with atypical liver function
Apr, 2029

(6 years from now)

US8754109 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(6 years from now)

US7816383 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(6 years from now)

US8648098 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(6 years from now)

US8013002 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(6 years from now)

US7910610 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(6 years from now)

US8084475 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(6 years from now)

US8318780 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(6 years from now)

US8778947 GENENTECH INC Methods of administering pirfenidone therapy
Aug, 2033

(10 years from now)

US10188637 GENENTECH INC Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
Mar, 2037

(14 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Market Authorisation Date: 11 January, 2017

Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition; Dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis; Dose escalation over 14 days for treatment of a fibrosis condition; Method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis; Dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Continued dosing or dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Continued dosing or dosage modification following elvated liver enzymes in use of pirfenidone; Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, then at least 1600mg/day in treatment of ipf; Dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by administering at least 1600 mg/day in treatment of ipf; Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-1600 mg/day, following by administering at least 1600 mg/day in treatment of ipf; Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-2400mg/day dose, followed by administering 2403mg/day in treatment of ipf; Dosing 2403 mg/day pirfenidone following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; Dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-1600 mg/day dose, followed by administering at least 1600 mg/day dose in treatment of ipf; Dosing of at least 1600 mg/day following grade 2 liver abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; Dosing of at least 1600 mg/day following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, followed by full daily dose in treatment of ipf; Administering pirfenidone while avoiding concomitant administration of a strong inducer of cyp1a2, including cigarette smoke, to avoid reduced pirfenidone efficacy; Discontinuing administration of fluvoxamine to avoid drug interactions with pirfenidone and then administering pirfenidone; Administering pirfenidone while avoiding co-administration of fluvoxamine to avoid drug interactions with pirfenidone; Discontinuing smoking to avoid reduced pirfenidone efficacy and then administering pirfenidone; Discontinuing administration of a strong cyp1a2 inducer to avoid reduced pirfenidone efficacy and then administering pirfenidone; Method for administering pirfenidone to reduce drug interactions with fluvoxamine; Administering pirfenidone while avoiding co-administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone; Discontinuing administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone and then administering pirfenidone; Discontinuing a strong cyp1a2 inducer to avoid reduced pirfenidone efficacy and then administering pirfenidone; Administering pirfenidone while avoiding concomitant administration of a strong inducer of cyp1a2 to avoid reduced pirfenidone efficacy; Method for administering pirfenidone while avoiding or discontinuing concomitant use of a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme involved in pirfenidone metabolism; Dose reduction of pirfenidone by about one half during concurrent administration of ciprofloxacin at a dose of 750 mg twice daily (1500 mg/day) to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder; Administration of pirfenidone and avoiding concurrent administration of ciprofloxacin at a dose of 750 mg to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder

Dosage: TABLET;ORAL

How can I launch a generic of ESBRIET before it's patent expiration?
More Information on Dosage

3. List of Evrysdi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9586955 GENENTECH INC Compounds for treating spinal muscular atrophy
Feb, 2033

(10 years from now)

US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 7, 2027
New Chemical Entity Exclusivity (NCE) Aug 7, 2025
New Patient Population (NPP) May 27, 2025

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: August, 2024

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

4. List of Gavreto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10030005 GENENTECH INC Inhibitors of RET
Nov, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273160 GENENTECH INC RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 4, 2025
Orphan Drug Exclusivity (ODE) Sep 4, 2027

Drugs and Companies using PRALSETINIB ingredient

NCE-1 date: September, 2024

Market Authorisation Date: 04 September, 2020

Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate); Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy

Dosage: CAPSULE;ORAL

More Information on Dosage

5. List of Rozlytrek drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9029356 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US8299057 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Mar, 2029

(6 years from now)

US9085565 GENENTECH INC Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(10 years from now)

US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616059 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US9085558 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US8673893 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US9255087 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US9649306 GENENTECH INC Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(10 years from now)

US10231965 GENENTECH INC Molecules for administration to ROS1 mutant cancer cells
Feb, 2035

(12 years from now)

US10561651 GENENTECH INC Methods for treating neuroblastoma
Feb, 2035

(12 years from now)

US11091469 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(14 years from now)

US11253515 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(15 years from now)

US10398693 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 15, 2026
New Chemical Entity Exclusivity (NCE) Aug 15, 2024

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 15 August, 2019

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of colorectal cancer that has a neurotrophic tyrosine receptor kinase(ntrk) gene fusion

Dosage: CAPSULE;ORAL

More Information on Dosage

6. List of Xofluza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8987441 GENENTECH INC Substituted polycyclic carbamoyl pyridone derivative prodrug
Sep, 2031

(8 years from now)

US10392406 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof
Apr, 2036

(13 years from now)

US10759814 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9815835 GENENTECH INC Substituted polycyclic carbamolypyridone derivative
Jun, 2030

(7 years from now)

US8927710 GENENTECH INC Substituted polycyclic carbamoylpyridone derivative
May, 2031

(8 years from now)

US10633397 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof
Apr, 2036

(13 years from now)

US11306106 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(14 years from now)

US11261198 GENENTECH INC Process for preparing substituted polycyclic pyridone derivative and crystal thereof
Sep, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 16, 2022
New Chemical Entity Exclusivity (NCE) Oct 24, 2023

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

NCE-1 date: October, 2022

Market Authorisation Date: 24 October, 2018

Treatment: Method for post-exposure prophylaxis of influenza; Method for treating influenza

Dosage: TABLET;ORAL

How can I launch a generic of XOFLUZA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in